Quote
49.85
-1.57 (-3.05%)
We have scored 59 news catalysts on CRSP (CRSP) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in sector healthcare and price momentum.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
49.83–52.12
Open
51.90
Prev close
51.42
Volume
401.2K
Avg volume
—
Dividend
—
IPO
—
No scored news tagged CRSP or its network in the window yet.
Show more CRSP articles →Analysts publish price targets on CRSP, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $55 to $80
as of 2026-09-05
The market is 18% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about CRSP — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of CRSP, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for CRSP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price sits 18% below the median analyst target and at the 17th percentile of the published spread, meaning the market believes the current cash reserves and approved therapy but refuses to pay for the pipeline's potential upside.
What the disagreement turns on
Whether the early clinical data for CTX310 and Zugo-cel will translate into viable, high-value therapies, a question that available wired data cannot settle because it requires clinical trial outcomes rather than consumer or volume metrics.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $55.79 on 2026-09-05 — the quote has since moved -11%, so read this as a record of what was priced in then, not now.
